142 related articles for article (PubMed ID: 31264494)
1. Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study.
Puolanne AM; Kolho KL; Alfthan H; Färkkilä M
Scand J Gastroenterol; 2019 Jul; 54(7):849-854. PubMed ID: 31264494
[No Abstract] [Full Text] [Related]
2. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease.
Gauss A; Geiss T; Hinz U; Schaefert R; Zwickel P; Zawierucha A; Stremmel W; Klute L
Medicine (Baltimore); 2016 Apr; 95(16):e3477. PubMed ID: 27100452
[TBL] [Abstract][Full Text] [Related]
4. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
Pedersen N
Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
[TBL] [Abstract][Full Text] [Related]
5. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
Kwapisz L; Gregor J; Chande N; Yan B; Ponich T; Mosli M
Scand J Gastroenterol; 2017 Aug; 52(8):846-850. PubMed ID: 28423962
[TBL] [Abstract][Full Text] [Related]
6. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
Elkjaer M
Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
[TBL] [Abstract][Full Text] [Related]
7. Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients.
Bello C; Roseth A; Guardiola J; Reenaers C; Ruiz-Cerulla A; Van Kemseke C; Arajol C; Reinhard C; Seidel L; Louis E
Dig Liver Dis; 2017 Sep; 49(9):991-996. PubMed ID: 28587751
[TBL] [Abstract][Full Text] [Related]
8. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease.
Östlund I; Werner M; Karling P
Scand J Gastroenterol; 2021 Jan; 56(1):38-45. PubMed ID: 33284639
[TBL] [Abstract][Full Text] [Related]
9. Self-managed eHealth Disease Monitoring in Children and Adolescents with Inflammatory Bowel Disease: A Randomized Controlled Trial.
Carlsen K; Jakobsen C; Houen G; Kallemose T; Paerregaard A; Riis LB; Munkholm P; Wewer V
Inflamm Bowel Dis; 2017 Mar; 23(3):357-365. PubMed ID: 28221247
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
12. Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial.
Ankersen DV; Weimers P; Marker D; Bennedsen M; Saboori S; Paridaens K; Burisch J; Munkholm P
World J Gastroenterol; 2019 Oct; 25(40):6158-6171. PubMed ID: 31686770
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
[TBL] [Abstract][Full Text] [Related]
14. Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic.
Jere M; Garrick V; Curtis L; Tayler R; Gervais L; Gerasimidis K; Hansen R
BMJ Open Gastroenterol; 2021 May; 8(1):. PubMed ID: 33947712
[TBL] [Abstract][Full Text] [Related]
15. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
16. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
17. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
18. IBDoc Canadian User Performance Evaluation.
Moore AC; Huang VW; Bourdages R; Fedorak RN; Reinhard C; Leung Y; Bressler B; Rosenfeld G
Inflamm Bowel Dis; 2019 May; 25(6):1107-1114. PubMed ID: 30535387
[TBL] [Abstract][Full Text] [Related]
19. A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients.
McCombie A; Walmsley R; Barclay M; Ho C; Langlotz T; Regenbrecht H; Gray A; Visesio N; Inns S; Schultz M
Inflamm Bowel Dis; 2020 Jun; 26(7):1098-1109. PubMed ID: 31644793
[TBL] [Abstract][Full Text] [Related]
20. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
Inflamm Bowel Dis; 2014 Feb; 20(2):307-14. PubMed ID: 24374878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
